INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update

~ Announces second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer’s disease (AD) ~ Cash and cash equivalents of $84.5 million on September 30th

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

4 COMMENTS

Cancel reply

Please enter your comment!
Please enter your name here